Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 monotherapy or AK104 + Lenvima in advanced hepatocellular carcinoma
CTR20210090Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Jan 2021
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Jan 2021; status: terminated.
02
Drugs
cadonilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20210090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210090.